PLNTY has been found to have a different DNA methylation signature [14], like BRAF mutation or fibroblast growth factor receptors 2 and 3 (FGFR2/FGFR3) translocation [11], involving the mitogen-activated protein kinase (MAPK) pathway [2, 3], lacking isocitrate dehydrogenase (IDH) mutations and 1p/19q codeletion (characteristic of Oligodendroglioma) [1]. This evidence concerns the gene FGFR2 and oligodendroglioma.